114 related articles for article (PubMed ID: 10815875)
1. Antisense approaches enter the clinic.
Khuri FR; Kurie JM
Clin Cancer Res; 2000 May; 6(5):1607-10. PubMed ID: 10815875
[No Abstract] [Full Text] [Related]
2. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
Cunningham CC; Holmlund JT; Schiller JH; Geary RS; Kwoh TJ; Dorr A; Nemunaitis J
Clin Cancer Res; 2000 May; 6(5):1626-31. PubMed ID: 10815879
[TBL] [Abstract][Full Text] [Related]
3. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).
O'Dwyer PJ; Stevenson JP; Gallagher M; Cassella A; Vasilevskaya I; Monia BP; Holmlund J; Dorr FA; Yao KS
Clin Cancer Res; 1999 Dec; 5(12):3977-82. PubMed ID: 10632328
[TBL] [Abstract][Full Text] [Related]
4. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.
Cripps MC; Figueredo AT; Oza AM; Taylor MJ; Fields AL; Holmlund JT; McIntosh LW; Geary RS; Eisenhauer EA
Clin Cancer Res; 2002 Jul; 8(7):2188-92. PubMed ID: 12114419
[TBL] [Abstract][Full Text] [Related]
5. Antisense approaches for the treatment of cancer.
Monia BP; Holmlund J; Dorr FA
Cancer Invest; 2000; 18(7):635-50. PubMed ID: 11036471
[No Abstract] [Full Text] [Related]
6. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
Rudin CM; Holmlund J; Fleming GF; Mani S; Stadler WM; Schumm P; Monia BP; Johnston JF; Geary R; Yu RZ; Kwoh TJ; Dorr FA; Ratain MJ
Clin Cancer Res; 2001 May; 7(5):1214-20. PubMed ID: 11350886
[TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease.
Green DW; Roh H; Pippin J; Drebin JA
J Am Coll Surg; 2000 Jul; 191(1):93-105. PubMed ID: 10898188
[No Abstract] [Full Text] [Related]
8. Technology evaluation: LErafAON, NeoPharm.
Moreira JN; Simões S
Curr Opin Mol Ther; 2003 Oct; 5(5):547-52. PubMed ID: 14601525
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
Geiger T; Müller M; Monia BP; Fabbro D
Clin Cancer Res; 1997 Jul; 3(7):1179-85. PubMed ID: 9815797
[TBL] [Abstract][Full Text] [Related]
10. Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo.
Gokhale PC; McRae D; Monia BP; Bagg A; Rahman A; Dritschilo A; Kasid U
Antisense Nucleic Acid Drug Dev; 1999 Apr; 9(2):191-201. PubMed ID: 10355825
[TBL] [Abstract][Full Text] [Related]
11. Regulation of c-Raf-1: therapeutic implications.
Beeram M; Patnaik A; Rowinsky EK
Clin Adv Hematol Oncol; 2003 Aug; 1(8):476-81. PubMed ID: 16258435
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
[TBL] [Abstract][Full Text] [Related]
13. First- and second-generation antisense oligonucleotide inhibitors targeted against human c-raf kinase.
Monia BP
Ciba Found Symp; 1997; 209():107-19; discussion 119-23. PubMed ID: 9383572
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor activity of C-raf antisense--correction.
Monia BP
Nat Med; 1999 Feb; 5(2):127. PubMed ID: 9930845
[No Abstract] [Full Text] [Related]
15. Antisense against protein kinase C-alpha mRNA makes sense for cancer therapy?
Stewart A
Mol Med Today; 1997 Aug; 3(8):324. PubMed ID: 9269683
[No Abstract] [Full Text] [Related]
16. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).
Stevenson JP; Yao KS; Gallagher M; Friedland D; Mitchell EP; Cassella A; Monia B; Kwoh TJ; Yu R; Holmlund J; Dorr FA; O'Dwyer PJ
J Clin Oncol; 1999 Jul; 17(7):2227-36. PubMed ID: 10561280
[TBL] [Abstract][Full Text] [Related]
17. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
[TBL] [Abstract][Full Text] [Related]
18. Antisense therapy in oncology: new hope for an old idea?
Tamm I; Dörken B; Hartmann G
Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
[TBL] [Abstract][Full Text] [Related]
19. Comparison of strategies targeting Raf-1 mRNA in ovarian cancer.
Mullen P; McPhillips F; Monia BP; Smyth JF; Langdon SP
Int J Cancer; 2006 Mar; 118(6):1565-71. PubMed ID: 16184551
[TBL] [Abstract][Full Text] [Related]
20. Cellular pharmacology of antisense oligodeoxynucleotides.
Schumacher C
Methods Enzymol; 2000; 314():440-54. PubMed ID: 10565031
[No Abstract] [Full Text] [Related]
[Next] [New Search]